JPH0271154A - Blood coagulating efficiency checking method by using whole blood - Google Patents
Blood coagulating efficiency checking method by using whole bloodInfo
- Publication number
- JPH0271154A JPH0271154A JP63223836A JP22383688A JPH0271154A JP H0271154 A JPH0271154 A JP H0271154A JP 63223836 A JP63223836 A JP 63223836A JP 22383688 A JP22383688 A JP 22383688A JP H0271154 A JPH0271154 A JP H0271154A
- Authority
- JP
- Japan
- Prior art keywords
- blood
- coagulation
- agent
- added
- coagulating
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008280 blood Substances 0.000 title claims abstract description 39
- 210000004369 blood Anatomy 0.000 title claims abstract description 39
- 230000001112 coagulating effect Effects 0.000 title abstract 3
- 238000000034 method Methods 0.000 title description 11
- 239000003146 anticoagulant agent Substances 0.000 claims abstract description 17
- 230000015271 coagulation Effects 0.000 claims abstract description 17
- 238000005345 coagulation Methods 0.000 claims abstract description 17
- 230000023555 blood coagulation Effects 0.000 claims abstract description 12
- 238000012360 testing method Methods 0.000 claims description 23
- 229940127219 anticoagulant drug Drugs 0.000 claims description 13
- 239000003999 initiator Substances 0.000 claims description 11
- 230000035602 clotting Effects 0.000 claims description 6
- 239000001509 sodium citrate Substances 0.000 abstract description 7
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 abstract description 6
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 abstract description 4
- 239000001110 calcium chloride Substances 0.000 abstract description 4
- 229910001628 calcium chloride Inorganic materials 0.000 abstract description 4
- 239000011575 calcium Substances 0.000 abstract description 3
- 229910052791 calcium Inorganic materials 0.000 abstract description 3
- 239000011521 glass Substances 0.000 abstract description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 abstract description 2
- -1 inorganic acid calcium salt Chemical class 0.000 abstract description 2
- 239000003795 chemical substances by application Substances 0.000 abstract 3
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 abstract 1
- 230000010100 anticoagulation Effects 0.000 abstract 1
- 239000011591 potassium Substances 0.000 abstract 1
- 229910052700 potassium Inorganic materials 0.000 abstract 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 7
- 229960002897 heparin Drugs 0.000 description 7
- 229920000669 heparin Polymers 0.000 description 7
- 238000001356 surgical procedure Methods 0.000 description 6
- 238000000502 dialysis Methods 0.000 description 5
- 206010053567 Coagulopathies Diseases 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- PGOHTUIFYSHAQG-LJSDBVFPSA-N (2S)-6-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-1-[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-4-methylsulfanylbutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]propanoyl]pyrrolidine-2-carbonyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]-3-sulfanylpropanoyl]amino]-4-methylsulfanylbutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-hydroxybutanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxybutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-oxopentanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-oxopentanoyl]amino]-3-phenylpropanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-oxobutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-4-carboxybutanoyl]amino]-5-oxopentanoyl]amino]hexanoic acid Chemical compound CSCC[C@H](N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(O)=O PGOHTUIFYSHAQG-LJSDBVFPSA-N 0.000 description 2
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 108010074860 Factor Xa Proteins 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 108010000499 Thromboplastin Proteins 0.000 description 2
- 102000002262 Thromboplastin Human genes 0.000 description 2
- 230000000740 bleeding effect Effects 0.000 description 2
- ZCCIPPOKBCJFDN-UHFFFAOYSA-N calcium nitrate Chemical compound [Ca+2].[O-][N+]([O-])=O.[O-][N+]([O-])=O ZCCIPPOKBCJFDN-UHFFFAOYSA-N 0.000 description 2
- 159000000007 calcium salts Chemical class 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- RBNPOMFGQQGHHO-UHFFFAOYSA-N -2,3-Dihydroxypropanoic acid Natural products OCC(O)C(O)=O RBNPOMFGQQGHHO-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- 108010039209 Blood Coagulation Factors Proteins 0.000 description 1
- 102000015081 Blood Coagulation Factors Human genes 0.000 description 1
- UNMYWSMUMWPJLR-UHFFFAOYSA-L Calcium iodide Chemical compound [Ca+2].[I-].[I-] UNMYWSMUMWPJLR-UHFFFAOYSA-L 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- RBNPOMFGQQGHHO-UWTATZPHSA-N D-glyceric acid Chemical compound OC[C@@H](O)C(O)=O RBNPOMFGQQGHHO-UWTATZPHSA-N 0.000 description 1
- 108010080805 Factor XIa Proteins 0.000 description 1
- 102000007327 Protamines Human genes 0.000 description 1
- 108010007568 Protamines Proteins 0.000 description 1
- 239000003568 Sodium, potassium and calcium salts of fatty acids Substances 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000003114 blood coagulation factor Substances 0.000 description 1
- 229940019700 blood coagulation factors Drugs 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- NKWPZUCBCARRDP-UHFFFAOYSA-L calcium bicarbonate Chemical compound [Ca+2].OC([O-])=O.OC([O-])=O NKWPZUCBCARRDP-UHFFFAOYSA-L 0.000 description 1
- 229910000020 calcium bicarbonate Inorganic materials 0.000 description 1
- 229910001622 calcium bromide Inorganic materials 0.000 description 1
- WGEFECGEFUFIQW-UHFFFAOYSA-L calcium dibromide Chemical compound [Ca+2].[Br-].[Br-] WGEFECGEFUFIQW-UHFFFAOYSA-L 0.000 description 1
- 229940046413 calcium iodide Drugs 0.000 description 1
- 229910001640 calcium iodide Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 235000013969 calcium salts of fatty acid Nutrition 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- IRXRGVFLQOSHOH-UHFFFAOYSA-L dipotassium;oxalate Chemical class [K+].[K+].[O-]C(=O)C([O-])=O IRXRGVFLQOSHOH-UHFFFAOYSA-L 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000001508 potassium citrate Substances 0.000 description 1
- 229960002635 potassium citrate Drugs 0.000 description 1
- QEEAPRPFLLJWCF-UHFFFAOYSA-K potassium citrate (anhydrous) Chemical compound [K+].[K+].[K+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O QEEAPRPFLLJWCF-UHFFFAOYSA-K 0.000 description 1
- 235000011082 potassium citrates Nutrition 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 229950008679 protamine sulfate Drugs 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- AWUCVROLDVIAJX-GSVOUGTGSA-N sn-glycerol 3-phosphate Chemical compound OC[C@@H](O)COP(O)(O)=O AWUCVROLDVIAJX-GSVOUGTGSA-N 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
Landscapes
- Investigating Or Analysing Biological Materials (AREA)
- Measurement Of The Respiration, Hearing Ability, Form, And Blood Characteristics Of Living Organisms (AREA)
- External Artificial Organs (AREA)
Abstract
Description
【発明の詳細な説明】
〔発明の技術分野〕
本発明は新規な全血を用いた血液凝固能検査法に関する
ものである。DETAILED DESCRIPTION OF THE INVENTION [Technical Field of the Invention] The present invention relates to a novel method for testing blood coagulation ability using whole blood.
一般に血液凝固能が亢進して速く凝固する場合ではたと
えば手術後血栓をおこすおそれがあり又これが抑制され
、なかなか凝固しない場合は手術部位からの出血が長引
くおそれがありいずれも危険である。特に人工心肺等の
機械を用いて手術を行なう場合或は人工透析を行なう場
合等血液を体外の機械に流すいわゆる体外循環の場合血
液は凝固し易いので抗凝固剤たるヘパリンを血液に入れ
てその凝固を防いでいる。従って手術する前、透析する
前でヘパリンが投与されていない血液や手術中又は人工
透析中ヘパリンを入れて循環させている血液の凝固能を
はかってその測定値又はその変動をチエツクして例えば
もしヘパリン投与による凝固能抑制が期待以上の場合、
思わぬ出血のおそれがあるためヘパリンを硫酸プロタミ
ンで中和するなど所要の処置をとって、血液凝固能の抑
制又は亢進からもたらされるおそれのある危険を回避す
るようにしている。In general, if blood coagulation ability is enhanced and coagulates quickly, there is a risk of, for example, thrombosis occurring after surgery, and if this is inhibited, if it does not coagulate easily, bleeding from the surgical site may be prolonged, both of which are dangerous. Particularly when performing surgery using a machine such as a heart-lung machine or when performing artificial dialysis, blood is easily coagulated in so-called extracorporeal circulation, such as when performing surgery or artificial dialysis. Blood tends to coagulate, so heparin, an anticoagulant, is added to the blood. Prevents coagulation. Therefore, before surgery or dialysis, the coagulation ability of blood to which heparin has not been administered, or blood that is circulating with heparin during surgery or artificial dialysis, is measured and the measured value or its fluctuation is checked. If the suppression of coagulation ability by heparin administration is greater than expected,
Since there is a risk of unexpected bleeding, necessary measures such as neutralizing heparin with protamine sulfate are taken to avoid the dangers that may result from suppression or enhancement of blood coagulation ability.
このように血液の凝固能が適正な値であるか否かを特に
手術時、人工透析時に検査することが必要でありこれを
検査する方法として種々のものがあるが、いくつかの問
題点があった。In this way, it is necessary to test whether the blood coagulation ability is at an appropriate value, especially during surgery or artificial dialysis, and there are various methods for testing this, but there are some problems. there were.
たとえば全血を用いる検査法としては、リ−・ホワイト
（Ｌｅｅ−Ｗｈｉｔｅ ）法、賦活凝固時間法、全血活
性化部分トロンボプラスチン時間があるが夫４次のよう
な問題点がある。For example, testing methods using whole blood include the Lee-White method, the activated clotting time method, and the whole blood activated partial thromboplastin time, but these methods have the following problems.
（１） Ｌｅｅ−Ｗｈｉｔｅ法、賦活凝固時間法は抗
凝固剤を用いないので、■採血後直ちに検査を実施しな
ければならないため、検査時期に融通性が無く、検査時
期を拘束される。■採血に時間がかかった場合検査値に
誤差を生ずる等の問題点があった。(1) Since the Lee-White method and the activated clotting time method do not use anticoagulants, (1) the test must be performed immediately after blood collection, so there is no flexibility in the test timing, and the test timing is restricted. ■There were problems such as errors in test values if blood sampling took a long time.
（２） 全血活性化部分トロンボプラスチン時間は操
作が２段階となっており繁雑である。■測定操作におい
て時間の正確さが検査値に影響するため、熟練した技術
がない場合には誤差を生ずる等の問題があった。(2) Whole blood activated partial thromboplastin time requires two steps and is complicated. ■Since the accuracy of time during measurement operations affects the test values, there are problems such as errors occurring in the absence of skilled techniques.
本発明はかかる問題点を解決して血液凝固能を迅速、簡
便に検査する方法を提供することを目的とするものであ
り、本発明者らの研究、実験によれば、抗凝固剤を加え
た全血に、凝固開始剤を添加し、凝固を形成するまでの
時間を測定することによってかかる目的が達成しうろこ
とが見出されたのである。The purpose of the present invention is to solve these problems and provide a method for quickly and easily testing blood coagulation ability. It was discovered that this objective could be achieved by adding a coagulation initiator to whole blood and measuring the time until clot formation.
〔発明の詳細な説明〕 本発明を以下詳細に説明する。[Detailed description of the invention] The present invention will be explained in detail below.
まず全血に抗凝固剤を加える。通常用いられる公知の抗
凝固剤がここでも用いられる。たとえば、３．８％クエ
ン酸ナトリウム、３．１２％クエン酸ナトリウム等の濃
度のクエン酸ナトリウム又はカリウムの水溶液、適当な
濃度のシュウ酸ナトリウム又はカリウム塩、エチレンジ
アミンテトラ酢酸（ＥＤＴＡ）の塩類又はその溶液等を
挙げることができる。たとえば、全血＋抗凝固剤の合計
量の約１０容量％の量の抗凝固剤が用いられる。これは
採血時に用いられる。First, an anticoagulant is added to whole blood. Commonly used known anticoagulants can be used here as well. For example, aqueous solutions of sodium or potassium citrate with concentrations such as 3.8% sodium citrate, 3.12% sodium citrate, sodium or potassium oxalate salts with appropriate concentrations, salts of ethylenediaminetetraacetic acid (EDTA), or the like. Solutions and the like can be mentioned. For example, an amount of anticoagulant is used that is approximately 10% by volume of the total amount of whole blood + anticoagulant. This is used when drawing blood.
このように抗凝固剤が添加された全血に凝固開始剤を加
える。ここに用いられる凝固開始剤としては、塩化カル
シウム、臭化カルシウム、ヨウ化カルシウム等のハロゲ
ン化カルシウム、リン酸カルシウム、硫酸カルシウム、
硝酸カルシウム、重炭酸カルシウム等の無機酸カルシウ
ム塩、蟻酸、酢酸、プロピオン酸、酪酸等の脂肪酸のカ
ルシウム塩、アルギン酸、グルコン酸、乳酸、グリセリ
ン酸、グリセロリン酸等の有機酸のカルシウム塩等の遊
離カルシウム供与体の水溶液があげられる。A coagulation initiator is added to the whole blood to which the anticoagulant has been added. The coagulation initiator used here includes calcium halides such as calcium chloride, calcium bromide, and calcium iodide, calcium phosphate, calcium sulfate,
Release of calcium salts of inorganic acids such as calcium nitrate and calcium bicarbonate, calcium salts of fatty acids such as formic acid, acetic acid, propionic acid, and butyric acid, and calcium salts of organic acids such as alginic acid, gluconic acid, lactic acid, glyceric acid, and glycerophosphoric acid. Examples include aqueous solutions of calcium donors.
凝固開始剤としては、この外活性化血液凝固第■因子（
ＩＸａ）、活性化血液凝固第Ｘ因子（Ｘａ）、活性化血
液凝固節ＸＩ因子（ＸＩａ）等も合わせて用いることが
できる。As a coagulation initiator, this extra-activated blood coagulation factor (
IXa), activated blood coagulation factor X (Xa), activated blood coagulation factor XI (XIa), etc. can also be used together.
このようにして凝固開始剤としてこれらの活性化因子を
併用するときは凝固塊の形成をより明瞭に測定すること
ができる。この中では塩化カルシウムの水溶液と活性化
血液凝固第Ｘ因子とを組合わせ用いるのが好ましい。In this way, when these activators are used together as coagulation initiators, the formation of clots can be measured more clearly. Among these, it is preferable to use a combination of an aqueous solution of calcium chloride and activated blood coagulation factor X.
血液凝固開始剤の添加は採血直後でもよ（、又氷冷に保
存しておけば後で添加して任意の時期に検査を開始する
ことも可能である。The blood coagulation initiator can be added immediately after blood collection (or, if stored on ice, it can be added later and the test can be started at any time).
検査は抗凝固剤を加えた全血に凝固開始剤を加えて測定
を開始し、注入されたガラス試験管を３７℃の水浴中に
３０秒間静止した後１０秒毎に取出してこれを傾斜させ
凝血塊が認められるまでの時間を計測する。ヘパリンネ
投与の正常者の場合１００秒前後で凝固しＱ、５Ｕ／ｍ
ｌのヘパリン血中濃度の場合も９分前後で凝固し通常長
くとも１５分以内で検査は終了する。The test begins by adding a coagulation initiator to whole blood containing an anticoagulant, and then the injected glass test tube is placed in a water bath at 37°C for 30 seconds, then taken out every 10 seconds and tilted. Measure the time until a clot is recognized. In a normal person receiving heparinne, it solidifies in around 100 seconds, Q, 5U/m
Even if the heparin blood concentration is 1, the blood will clot in about 9 minutes, and the test will normally be completed within 15 minutes at the most.
実施例１
凝固開始剤（０，０６２５Ｍ塩化カルシウム、０．２Ｕ
／ｍｌ Ｘａ）０．２ｍｌ
血液（３，８％クエン酸ナトリウム１容＋血液９容）１
ｍｌ
をガラス試験管に注入しｎ１定を開始させ、３０秒間３
７℃の水浴中に静止した後１０秒毎に試験管を傾斜させ
凝血塊が認められるまでの時間を計測する。Example 1 Coagulation initiator (0,0625M calcium chloride, 0.2U
/ml Xa) 0.2ml Blood (1 volume of 3.8% sodium citrate + 9 volumes of blood) 1
ml into a glass test tube to start n1 constant, and hold for 30 seconds.
After resting in a water bath at 7°C, the test tube is tilted every 10 seconds and the time until a clot is observed is measured.
ヘパリンネ投与の正常者３２名について検査を実施した
ときの測定値分布を表に示す。これをグラフに示せば第
１図のとおりである。はぼ７０〜１８０秒の範囲であり
、その中９０％は８０〜凝固時間（秒） 例数 凝固時
間（秒） 例数計３２
１０５．０（秒）±２２．６（秒）
（平均値上標準偏差）
〔効 果〕
このように本発明によるときは、採血時に抗凝固剤を用
いるため、採血後検体を保存し後で任意の時期に凝固開
始剤を添加して検査を開始することも可能であり、検査
時間を任意に選択することができる。又採血に時間を要
する時も抗凝固剤の添加により血液凝固の開始が防止さ
れているため検査面に影響を与えることはなく誤差が生
じにくい。The table shows the distribution of measured values when testing was carried out on 32 normal subjects administered heparinne. This is shown in a graph as shown in Figure 1. 90% of them are in the range of 70 to 180 seconds, and 90% of them are 80 to clotting time (seconds) Number of cases Clotting time (seconds) Total number of cases 32 105.0 (seconds) ± 22.6 (seconds) (Average value (Upper standard deviation) [Effect] As described above, according to the present invention, since an anticoagulant is used during blood collection, the sample can be stored after blood collection, and a coagulation initiator can be added at any time later to start the test. is also possible, and the inspection time can be arbitrarily selected. Furthermore, even when it takes time to collect blood, the addition of an anticoagulant prevents the start of blood coagulation, so it does not affect the test surface and errors are less likely to occur.
又一般的に抗凝固剤を用いるときは血漿分離等の試験操
作を行なう等煩雑な操作を必要とし簡便に血液凝固能の
４１１定ができなかったが、本発明では血漿分離等の繁
雑な操作を省き全血に凝固開始剤を添加することによっ
て簡便に血液凝固能をａ１定することができるようにな
った。更に従来の方法では１０分以上の時間を必要とし
たが本発明のときは通常数分間で終了でき迅速に検査す
ることができる。In addition, generally when using an anticoagulant, complicated operations such as plasma separation are required, making it impossible to easily determine blood coagulation ability.However, in the present invention, complicated operations such as plasma separation are required. Blood coagulation ability can now be easily determined by adding a coagulation initiator to whole blood. Furthermore, while the conventional method required 10 minutes or more, the present invention can usually be completed in a few minutes, allowing for rapid testing.
尚本発明は全血を用いた血液凝固能検査法に関するが、
例えばヘパリン等の抗凝固剤を投与された患者の血液に
ついても検査が可能となる。Although the present invention relates to a blood coagulation ability testing method using whole blood,
For example, it is also possible to test the blood of patients who have been administered anticoagulants such as heparin.
図面第１図は本発明の方法の一実施例の測定結果を示す
グラフである。FIG. 1 is a graph showing the measurement results of an embodiment of the method of the present invention.
Claims (1)
成するまでの時間を測定することを特徴とする、全血を
用いた血液凝固能検査法。A blood coagulation ability testing method using whole blood, which is characterized by adding a coagulation initiator to whole blood containing an anticoagulant and measuring the time until clot formation.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP63223836A JP2746386B2 (en) | 1988-09-07 | 1988-09-07 | Blood coagulation test using whole blood |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP63223836A JP2746386B2 (en) | 1988-09-07 | 1988-09-07 | Blood coagulation test using whole blood |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPH0271154A true JPH0271154A (en) | 1990-03-09 |
| JP2746386B2 JP2746386B2 (en) | 1998-05-06 |
Family
ID=16804482
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP63223836A Expired - Fee Related JP2746386B2 (en) | 1988-09-07 | 1988-09-07 | Blood coagulation test using whole blood |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP2746386B2 (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2007218279A (en) * | 2006-02-14 | 2007-08-30 | Hioki Ee Corp | Displacement magnifying mechanism with displacement final output end and processing apparatus provided with the displacement magnifying mechanism |
| US20150240287A1 (en) * | 2012-09-28 | 2015-08-27 | Chugai Seiyaku Kabushiki Kaisha | Method for evaluating blood coagulation reaction |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS60115519A (en) * | 1983-11-28 | 1985-06-22 | Sekisui Chem Co Ltd | Promotor for blood clotting |
| JPS6122255A (en) * | 1983-01-26 | 1986-01-30 | ユニバ−シテイ− オブ メデイシン アンド デンテイストリ− オブ ニユ−ジヤ−ジ | Hematological predicting and inspection method of septicemiaand other symptom |
-
1988
- 1988-09-07 JP JP63223836A patent/JP2746386B2/en not_active Expired - Fee Related
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6122255A (en) * | 1983-01-26 | 1986-01-30 | ユニバ−シテイ− オブ メデイシン アンド デンテイストリ− オブ ニユ−ジヤ−ジ | Hematological predicting and inspection method of septicemiaand other symptom |
| JPS60115519A (en) * | 1983-11-28 | 1985-06-22 | Sekisui Chem Co Ltd | Promotor for blood clotting |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2007218279A (en) * | 2006-02-14 | 2007-08-30 | Hioki Ee Corp | Displacement magnifying mechanism with displacement final output end and processing apparatus provided with the displacement magnifying mechanism |
| US20150240287A1 (en) * | 2012-09-28 | 2015-08-27 | Chugai Seiyaku Kabushiki Kaisha | Method for evaluating blood coagulation reaction |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2746386B2 (en) | 1998-05-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Basile et al. | Percent reduction in blood urea concentration during dialysis estimates Kt/V in a simple and accurate way | |
| Ruttmann et al. | Haemodilution-induced enhancement of coagulation is attenuated in vitro by restoring antithrombin III to pre-dilution concentrations | |
| Kudo et al. | Importance of monitoring the circulating blood volume in patients with cerebral vasospasm after subarachnoid hemorrhage | |
| JP4267592B2 (en) | Antithrombotic drug efficacy test method | |
| US20090192137A1 (en) | Dialysis method | |
| Jaberi et al. | Control of heparin therapy in open-heart surgery | |
| Ziai et al. | The effect of oral anticoagulation on clotting during hemodialysis | |
| US4067777A (en) | Determination of heparin in the blood | |
| Peden Jr et al. | Use of the plasma thrombin time to assess the adequacy of in vivo neutralization of heparin: comparative studies following operations employing extracorporeal circulation | |
| CN109709292B (en) | A heparin detection kit and its application | |
| JPH0271154A (en) | Blood coagulating efficiency checking method by using whole blood | |
| JP2954239B2 (en) | Simple blood coagulation test equipment for whole blood | |
| Celoria et al. | Effects of acute lower limb ischemia on femoral venous efflux | |
| Harloff et al. | Comparison study of the hepcon system four and the hemostasis management system | |
| Mager et al. | The early course of D-dimer concentration following pulmonary artery embolisation | |
| Kase et al. | Factors affecting the activated clotting time | |
| RU2840929C1 (en) | Method for prediction of complications in cardioembolic ischemic stroke with underlying heparin therapy | |
| Stefanidis et al. | Influence of hematocrit on hemostasis in continuous venovenous hemofiltration during acute renal failure | |
| EP0668926B1 (en) | Multiple coagulation test device and method | |
| CN119619482A (en) | Method and kit for detecting heparin or low molecular weight heparin in blood samples | |
| Carroll et al. | The future of activated clotting time? | |
| 임현재 | Impact of renal replacement therapy modality on coagulation and platelet function in critically ill patients | |
| RU2000571C1 (en) | Method of determination of hemostasis system individual sensitivity in patients with ischemic heart disease for treatment with obsidan and finoptin | |
| Wang et al. | MO662 EFFECT OF ARTERIOVENOUS VASCULAR ACCESS ON BIOIMPEDANCE MEASUREMENTS IN HEMODIALYSIS PATIENTS | |
| Kohtz et al. | Effects of ultrafiltration on enoxaparin: an in vitro analysis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| LAPS | Cancellation because of no payment of annual fees |